State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption

MOUNTAIN VIEW, Calif., Dec. 18, 2013 /PRNewswire/ -- Tissue engineering is a rapidly diversifying technology that emerged as a regenerative or reparative medicine with potential to circumvent organ shortage globally. Extensive developments in tissue engineering, which involve leveraging technologies from biomaterials, molecular medicine, biochemistry, nanotechnology, genetic, and biomedical engineering, target the restructure and/or repair of human organs through regeneration and cell expansion.

In recent years, cell-based technologies and the integration of genetics – with the use of biological substitutes that aim to restore, maintain or enhance tissue function – have been a popular approach for tissue regeneration and reparation treatment, according to Frost & Sullivan's Advances in Tissue Engineering and Organ Regeneration: Technology Market Penetration and Roadmapping analysis (http://www.technicalinsights.frost.com).

For more information on this research, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com.

Tissue engineering has been a field marked by extensive research and development (R&D), and companies take several years to commercially launch products.

"Still considered a nascent science, research in the field has offered and continues to offer an increasing number of substitutes for applications that would enable the human body to withstand pain and injuries," said Frost & Sullivan Technical Insights Industry Analyst Darshana De. "Apart from previous applications such as the common regeneration of bone, cartilage and skin, current targets have expanded to cardiovascular, kidney, pancreas, liver, spine, ligament, esophagus, cornea, thoracic, lung, nerve, lymphatic and blood vessels."

Despite this expanding capability and the technology's remarkable impact on the healthcare sector, tissue engineers need to overcome many challenges for their field to gain recognition as a mainstream medical technology. For instance, safety and efficacy remain top concerns with several products still undergoing research studies for their validation. Therefore, most patients continue to opt for treatment by medication and the usage of medical devices for temporary relief of symptoms.

Nevertheless, regenerative medicine has immense scope as a disruptive technology, especially as a number of medical device and pharmaceutical companies are conducting R&D through mergers and acquisitions with smaller companies or partnerships with the academic sector.

"As a result, stem cells and cell transplantation technology have evolved from a lab-based research hypothesis model into an applicable treatment mode for patients," observed De. "Recent advancements in molecular biology tools, imaging equipment, and cellular mechanism elucidation could provide more discoveries, substantiation, and an improved R&D process for cell-based therapies."

The convergence of these methodologies and equipment will open up new opportunities for different stakeholders and quicken market penetration.

Advances in Tissue Engineering and Organ Regeneration: Technology Market Penetration and Roadmapping, a part of the Technical Insights subscription, details the advancements in tissue engineering technology and provides an overview of the value chain networks existing in this domain. The study analyzes the market impact of innovations in tissue engineering and organ regeneration, key business accelerators and challenges, and end-user demand. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

Connect with us on social media, including Twitter, Facebook, SlideShare, and LinkedIn, for the latest news and updates.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation. The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Advances in Tissue Engineering and Organ Regeneration: Technology Market Penetration and Roadmapping
D506-TI

Contact:
Jennifer Carson
Corporate Communications – North America
P: 210.247.2450
E: jennifer.carson@frost.com

LinkedIn: Transform Health Group
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan

http://www.frost.com
http://www.technicalinsights.frost.com

SOURCE Frost & Sullivan

RELATED LINKS
http://www.frost.com